Trial Profile
Phase I Study of Abexinostat and Ibrutinib in Diffuse Large B-cell Lymphoma and Mantle Cell Lymphoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 11 Jun 2023
Price :
$35
*
At a glance
- Drugs Abexinostat (Primary) ; Ibrutinib (Primary)
- Indications Diffuse large B cell lymphoma; Mantle-cell lymphoma
- Focus Adverse reactions
- 11 Aug 2022 Status changed from recruiting to active, no longer recruiting.
- 01 Jul 2022 Planned End Date changed from 1 May 2023 to 1 May 2024.
- 01 Jul 2022 Planned primary completion date changed from 1 May 2023 to 1 May 2024.